2025-08-03 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data. The report is structured to provide a clear and concise overview of the stock's performance and outlook.

## JNJ Stock Analysis

**Company Overview:** Johnson & Johnson is a global healthcare giant focused on pharmaceuticals, medical devices, and consumer health products.

**1. Performance vs. S&P 500 (VOO)**

*   **JNJ Cumulative Return:** 12.61%
*   **VOO Cumulative Return:** 94.15%
*   **Absolute Divergence:** -72.2%
*   **Relative Divergence:** 6.2 (on a scale where the min-max range of divergence is 0-100)
    *   This indicates significant underperformance compared to the S&P 500 over the evaluated period. The relative divergence suggests JNJ is near the lower end of its historical divergence range compared to the index.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| ---------- | ------ | ------ | ------- | ------ | ------ |
| 2015-2017  | -1.0%  | 0.0%   | -30.0%  | -31.3  | 336.5  |
| 2016-2018  | -9.0%  | 56.5%  | -27.0%  | -1.0   | 310.8  |
| 2017-2019  | 7.0%   | 56.5%  | -23.0%  | -1.2   | 351.3  |
| 2018-2020  | 22.0%  | 58.6%  | 2.0%    | -0.1   | 379.0  |
| 2019-2021  | 35.0%  | 59.4%  | -13.0%  | 0.4    | 412.0  |
| 2020-2022  | 12.0%  | 61.3%  | 10.0%   | 0.8    | 425.4  |
| 2021-2023  | -9.0%  | 61.3%  | -27.0%  | 0.7    | 377.5  |
| 2022-2024  | -28.0% | 61.3%  | -54.0%  | 0.4    | 348.3  |
| 2023-2025  | -1.0%  | 70.1%  | -47.0%  | 0.1    | 403.0  |

*   **Analysis:** The table reveals fluctuating performance over different periods. JNJ has demonstrated negative Alpha values in most periods, indicating underperformance relative to its expected return based on its Beta. The Beta values are generally low, suggesting low volatility compared to the market, but recent periods show this correlation is becoming slightly positive. MDD (Maximum Drawdown) values are significant.

**2. Recent Price Action**

*   **Current Price:** 167.33
*   **Last Market Data:** Price: 167.33, Previous Close: 164.74, Change: 1.57 (A notable increase).
*   **Moving Averages:**
    *   5-day MA: 166.73
    *   20-day MA: 162.90
    *   60-day MA: 156.59

*   **Analysis:** The stock price is above all three moving averages, suggesting a short-term upward trend. The recent price increase indicates positive momentum.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3358 (Low Risk)
*   **RSI:** 67.05 (Approaching overbought territory)
*   **PPO:** 0.0093
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (4 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00)
*   **Delta of Relative Divergence (20-day):** -2.7 (Short-term decrease in relative divergence)
*   **Expected Return:** -458.9% (Long-term, relative to S&P 500)

*   **Analysis:** The MRI suggests low market risk. The RSI indicates the stock is nearing overbought conditions. The PPO is slightly positive. The hybrid signal suggests a cautious buying approach. The negative change in relative divergence indicates recent underperformance compared to the S&P 500. The extremely negative expected return is a major red flag for long-term investment.

**4. Recent News & Significant Events**

*   **News Summary:** Recent headlines highlight potential business developments, regulatory changes, market events, analyst discussions, and stock volatility. Investors are advised to monitor news and company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출         |
| ---------- | ---- | ------------ |
| 2025-07-24 | 2.30 | 23.74 B$     |
| 2025-04-23 | 4.57 | 21.89 B$     |
| 2024-10-23 | 1.12 | 22.47 B$     |
| 2024-07-25 | 1.95 | 22.45 B$     |
| 2025-07-24 | 1.95 | 22.45 B$     |

*   **Analysis:** The recent earnings show fluctuating EPS figures. The most recent quarter shows revenue growth, but it will be important to watch the trend over time.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | ------------- |
| 2025-06-30   | $23.74B   | 67.87%        |
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |
| 2024-06-30   | $22.45B   | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
| ------------ | --------- | ------- |
| 2025-06-30   | $78.47B   | 7.06%   |
| 2025-03-31   | $78.11B   | 14.08%  |
| 2024-12-31   | $71.49B   | 4.80%   |
| 2024-09-30   | $70.16B   | 3.84%   |
| 2024-06-30   | $71.54B   | 6.55%   |

*   **Analysis:** JNJ maintains high profit margins, indicating strong pricing power. Revenue has shown some growth.  ROE (Return on Equity) fluctuates, indicating varying efficiency in generating profit from shareholder equity.

**7. Summary and Overall Analysis**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500.
*   **Recent Momentum:**  Recent price action suggests short-term positive momentum, but the RSI is nearing overbought levels.
*   **Long-Term Concerns:** The deeply negative expected return raises serious concerns about the long-term investment prospects.
*   **Financial Health:** Strong profit margins and consistent revenue are positive.
*   **News and Events:** Recent news suggest volatility and potential changes impacting JNJ.

**Conclusion:**

While JNJ exhibits financial stability and recent positive price momentum, the substantial underperformance relative to the S&P 500 and the alarming negative expected return warrant significant caution. Investors should carefully consider the potential risks and conduct thorough due diligence before making any investment decisions. Monitoring the company's response to recent news events and analyzing future earnings reports will be critical.
